Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

Market Cap	50.75B +49.0%
Revenue (ttm)	4.27B +14.7%
Net Income	308.94M -35.1%
EPS	0.27 -36.7%
Shares Out	1.11B
PE Ratio	167.30
Forward PE	97.34
Dividend	0.42 (0.88%)
Ex-Dividend Date	n/a

Volume	3,111,200
Average Volume	3,635,939
Open	47.16
Previous Close	47.07
Day's Range	43.91 - 48.47
52-Week Range	33.01 - 62.65
Beta	-0.06
RSI	45.43
Earnings Date	Apr 13, 2026

About SHE:002653

Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. The company offers pharmaceutical products in the areas of anesthesia and analgesia, diabetes mellitus and complications, tumor, neuralgia, parenteral nutrition, cardio-cerebrovascular, digestive and respiratory, narcotic analgesics, endocrine system, enteral parenteral, nutrition, neuropsychiatric, cardiovascular, digestive liver, and other diseases. The company was formerly known as Xizang Haisco Pharmaceutical Group...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 5,337
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002653

Financial Performance

In 2024, SHE:002653's revenue was 3.72 billion, an increase of 10.92% compared to the previous year's 3.36 billion. Earnings were 395.46 million, an increase of 34.00%.